Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243122 | 0.89 | PRMT5 (0.31) | PRMT5WDR77 | |
| SCHEMBL22972695 | 0.89 | PI4KA (0.39) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL12243161 | 0.89 | PIK3CD (0.32) | PRMT5WDR77RXFP1 | |
| SCHEMBL12243172 | 0.88 | PRMT5 (0.30) | PRMT5WDR77 | |
| SCHEMBL12243175 | 0.84 | SMYD2 (0.32) | PRMT5WDR77 | |
| SCHEMBL15084425 | 0.84 | SMYD2 (0.32) | PRMT5WDR77 | |
| SCHEMBL12243207 | 0.84 | TMPRSS2 (0.36) | PRMT5WDR77 | |
| SCHEMBL18636479 | 0.79 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26878947 | 0.79 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12243124 | 0.78 | HPGD (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | PRMT5 1367/4885WDR77 2418/4885PI4KA 402/4885 |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, CDA | PRMT5 1560/4885WDR77 2455/4885PI4KA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.